肠安康新组方抗溃疡性结肠炎大鼠的机制研究

摘要

Aim To observe inducible nitric oxide syn-thase ( iNOS ) activity, nitricoxide( NO ) levels, inter-leukin-8( IL-8 )levels, and c-Jun expression in colonic tissue to evaluate the possible mechanism of oral administration and colon-specific drug delivery of new Chang-an-kang. Methods Trinitrobenzene sulfonic acid( TNBS )/ethanol-induced ulcerative colitis ( UC ) rat model was prepared, and the model rats were randomly divided into eight groups: model control group, sulfasalazine tablets( SASP ) group, 1. 12,0. 56,0. 28 g · kg-1 oral administration group and 1.12,0.56, 0. 28 g · kg-1 colon-specific drug delivery group. Rats were given drugs after 24 h of modeling for 7 days successively , and on the 9 th day , iNOS activity, NO levels, IL-8 levels, and c-Jun expression were detected.There was a significant increase in iNOS activity, NO levels, IL-8 levels, and c-Jun expression between normal group and model group. Oral administration and colon-specific drug delivery of new Chang-an-kang decreased iNOS activity, NO levels, IL-8 levels, and c-Jun expression, and colon-specific drug delivery were better than oral administration. Conclusions Oral administration and colon-specific drug delivery of new Chang-an-kang may play their therapeutic role through inhibiting the inflammation due to iNOS, NO, IL-8 generation and c-Jun activation.%目的 研究肠安康新组方抗溃疡性结肠炎(UC)大鼠可能的作用机制.方法 制备三硝基苯磺酸(TNBS)/乙醇诱导溃疡性结肠炎(UC)大鼠模型,动物随机分为9组:正常对照组、模型对照组、柳氮磺胺吡啶(SASP)组、肠安康新组方口服给药组(1.12、0.56、0.28 g*kg-1)、肠安康新组方结肠定位给药组(1.12、0.56、0.28 g*kg-1).造模后24 h开始给药,每天1次,连续给药7 d,从造模开始至实验结束共9 d.实验结束后紫外分光光度法测诱导型一氧化氮合酶(Inos)活性、一氧化氮(NO)含量,ELISA法测白介素-8(IL-8)含量,免疫组化法检测c-Jun表达.结果 与模型组相比,肠安康新组方各给药组均可改善升高的Inos、NO、IL-8、c-Jun.结论 肠安康新组方抗UC作用可能与抑制炎症因Inos、NO、IL-8的产生和c-Jun的激活有关.